Hostname: page-component-77f85d65b8-9nbrm Total loading time: 0 Render date: 2026-03-27T13:22:56.903Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Zubkow et al. “Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis”

Published online by Cambridge University Press:  27 March 2026

Nabeela Nathoo Open the ORCID record for Nabeela Nathoo [Opens in a new window]
Nabeela Nathoo*
Affiliation:
Division of Neurology, Department of Medicine and Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada
*
Corresponding author: Nabeela Nathoo; Email: nnathoo@ualberta.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Longbrake, EE, Naismith, RT, Parks, BJ, Wu, GF, Cross, AH. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015;1:1–8. DOI: 10.1177/2055217315596994.Google ScholarPubMed
Jordan, ALM, Yang, J, Fisher, CJ, Racke, MK, Mao-Draayer, Y. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler. 2022;28:7–15. DOI: 10.1177/1352458520949158.10.1177/1352458520949158CrossRefGoogle ScholarPubMed
Zubkow, K, Kim, MY, Kahovec, C, et al. Disease activity following cessation of dimethyl fumarate in patients with relapsing-remitting multiple sclerosis. Can J Neurol Sci. 2026; 1–15.10.1017/cjn.2026.10536CrossRefGoogle ScholarPubMed
Chan, A, Rose, J, Alvarez, E, et al. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurol Clin Pract. 2020;10:510–9. DOI: 10.1212/CPJ.0000000000000800.10.1212/CPJ.0000000000000800CrossRefGoogle ScholarPubMed
de Seze, J, Labauge, P, Liblau, R, et al. LymphoTEC: a retrospective real-world study on lymphocyte reconstitution after lymphopenia in patients with multiple sclerosis treated with dimethyl fumarate in France. Adv Ther. 2025;42:1760–82. DOI: 10.1007/s12325-024-03092-5.10.1007/s12325-024-03092-5CrossRefGoogle Scholar
Chu, L, Balusha, A, Casserly, C, Berger, W, Morrow, SA. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate. Mult Scler Relat Disord. 2022;57:103384. DOI: 10.1016/j.msard.2021.103384.10.1016/j.msard.2021.103384CrossRefGoogle ScholarPubMed